Serum levels of S100B and NSE proteins in Alzheimer’s disease patients

• Autor(a) principal: Chaves, Marcia Lorena Fagundes
• Data de Publicação: 2010
• Outros Autores: Pádua, Analuiza Camozzato de, Ferreira, Eduardo Daura, Piazenski, Isabel, Kochhann, Renata, Dall'Igna, Oscar Phelippe Permigotti, Mazzini, Guilherme da Silva, Souza, Diogo Onofre Gomes de, Portela, Luis Valmor Cruz
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/24135
• topic: Doença de Alzheimer; Fosfopiruvato hidratase; Proteínas S100

Background: Alzheimer’s disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention. Methods: We evaluated serum levels of S100B and neuron-specific enolase (NSE) in 54 mild, moderate and severe Alzheimer’s disease (AD) patients and in 66 community-dwelling elderly. AD patients met the probable NINCDSADRDA criteria. Severity of dementia was ascertained by the Clinical Dementia Rating (CDR) scale, cognitive function by the Mini Mental State Examination (MMSE), and neuroimage findings with magnetic resonance imaging. Serum was obtained from all individuals and frozen at -70°C until analysis. Results: By comparing both groups, serum S100B levels were lower in AD group, while serum NSE levels were the same both groups. In AD patients, S100B levels were positively correlated with CDR scores (rho = 0.269; p = 0.049) and negatively correlated with MMSE scores (rho = -0.33; P = 0.048). NSE levels decreased in AD patients with higher levels of brain atrophy. Conclusions: The findings suggest that serum levels of S100B may be a marker for brain functional condition and serum NSE levels may be a marker for morphological status in AD.